drugset / Trial / NCT02362412

Study to Evaluate the Effects of Switching Different Strength Forms of FK949E in Bipolar Disorder Patients With Major Depressive Episodes

NCT02362412

Phase 3 Completed 22 enrolled Astellas Pharma Inc
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study was to evaluate the efficacy, safety, and pharmacokinetics of switching FK949E (sustained-release quetiapine) 50-mg and 150-mg tablets to the other tablet at the equivalent total daily dose in bipolar disorder patients with major depressive episodes.

Timeline

Start
2015-02-18
Primary completion
2016-02-06
Completion
2016-02-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Quetiapine Small molecule 50 mg Oral
Subject Quetiapine Small molecule 150 mg Oral

Indications